Pharmacotherapy for obesity in menopausal women.
Weight gain, during and after the menopause is common. Contributing factors include ethnicity, reduced physical activity, reduced lean mass, reduced resting metabolic rate and treatment with certain drugs, e.g. steroids, insulin, glitazones. Excess body weight increases the risk of medical conditions including type 2 diabetes, hypertension, osteoarthritis, certain cancers and is associated with increased mortality. This review examines pharmacological approaches to promote weight loss. Pharmacological therapy should be considered as an adjunct to diet and lifestyle changes. The licensed drugs orlistat, sibutramine and rimonabant are discussed. Obesity increases the risk of type 2 diabetes. Thus, the effects of metformin and exenatide are examined.
Samat
Ashish
A
Department of Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham, UK. ashishsamat@hotmail.com
Rahim
Asad
A
Barnett
Anthony
A
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D050110:Bariatric Surgery; D003503:Cyclobutanes / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000209:etiology; D000077270:Exenatide; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007783:Lactones / Q000627:therapeutic use; D008593:Menopause; D008687:Metformin; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D000077403:Orlistat; D010455:Peptides / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D000077285:Rimonabant; D012307:Risk Factors; D014688:Venoms / Q000627:therapeutic use
D019440:Anti-Obesity Agents; D003503:Cyclobutanes; D007004:Hypoglycemic Agents; D007783:Lactones; D010455:Peptides; D010880:Piperidines; D011720:Pyrazoles; D014688:Venoms; D008687:Metformin; D000077403:Orlistat; D000077270:Exenatide; D000077285:Rimonabant; C058254:sibutramine